Possible relationship between changes in islet neogenesis and islet neogenesis-associated protein-positive cell mass induced by sucrose administration to normal hamsters.
The possible relationship between changes in islet cell mass and in islet neogenesis-associated protein (INGAP)-cell mass induced by sucrose administration to normal hamsters was investigated. Normal hamsters were given sucrose (10% in drinking water) for 5 (S8) or 21 (S24) weeks and compared with control (C) fed hamsters. Serum glucose and insulin levels were measured and quantitative immunocytochemistry of the endocrine pancreas was performed. Serum glucose levels were comparable among the groups, while insulin levels were higher in S hamsters. There was a significant increase in beta-cell mass (P<0.02) and in beta-cell 5-bromo-2'-deoxyuridine index (P<0.01), and a significant decrease in islet volume (P<0.01) only in S8 vs C8 hamsters. Cytokeratin (CK)-labelled cells were detected only in S8 hamsters. INGAP-positive cell mass was significantly larger only in S8 vs C8 hamsters. Endocrine INGAP-positive cells were located at the islet periphery ( approximately 96%), spread within the exocrine pancreas ( approximately 3%), and in ductal cells (<1%) in all groups. INGAP positivity and glucagon co-localization varied according to topographic location and type of treatment. In C8 hamsters, 49.1+/-6. 9% cells were INGAP- and glucagon-positive in the islets, while this percentage decreased by almost half in endocrine extra-insular and ductal cells. In S8 animals, co-expression increased in endocrine extra-insular cells to 36.3+/-9.5%, with similar figures in the islets, decreasing to 19.7+/-6.9% in ductal cells. INGAP-positive cells located at the islet periphery also co-expressed CK. In conclusion, a significant increase of INGAP-positive cell mass was only observed at 8 weeks when neogenesis was present, suggesting that this peptide might participate in the control of islet neogenesis. Thus, INGAP could be a potentially useful tool to treat conditions in which there is a decrease in beta-cell mass.
Del Zotto
H
H
CENEXA - Center of Experimental and Applied Endocrinology (UNLP-CONICET, WHO Collaborating Center), University of La Plata School of Medicine, La Plata, Argentina.
Massa
L
L
Rafaeloff
R
R
Pittenger
G L
GL
Vinik
A
A
Gold
G
G
Reifel-Miller
A
A
Gagliardino
J J
JJ
D000818:Animals; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D006224:Cricetinae; D004326:Drinking; D004435:Eating; D005455:Fluorescent Antibody Technique; D007328:Insulin / Q000097:blood; D007515:Islets of Langerhans / Q000166:cytology / Q000378:metabolism / Q000502:physiology*; D007633:Keratins / Q000378:metabolism; D037181:Lectins, C-Type; D008297:Male; D000073718:Pancreatitis-Associated Proteins; D011506:Proteins / Q000378:metabolism*; D012038:Regeneration / Q000187:drug effects*; D013395:Sucrose / Q000494:pharmacology*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D001786:Blood Glucose; D007328:Insulin; D037181:Lectins, C-Type; D000073718:Pancreatitis-Associated Proteins; D011506:Proteins; C000612141:REG3A protein, human; D013395:Sucrose; D007633:Keratins